Home / Drug development / Preclinical / Solid state chemistry
Crystallization expertise
We provide solid-state chemistry R&D services to explore, identify, optimize, and scale the most desired and manufacturable forms of your drug substance for preclinical and clinical use. Our teams perform salt selection and polymorphic form screening with high throughput tools and automation methods. Identified forms are fully characterized to understand stability, solubility, and bioavailability properties.
Our expertise in scale-up and crystallization process development is seamlessly applied to make the desired form on a bulk manufacturing scale. Integrated with our drug discovery services, pharmaceutical process development and formulation services, our approach allows for science-based decision making in clinical candidate selection and a seamless implementation into GMP manufacturing for preclinical and clinical development.
Capabilities include:
- High throughput Solid-form screening – Exploration of the salt-, polymorph- and co-crystal landscape of your API using advanced high throughput screening methods and lab automation. Expect short turn around times, minimal material usage and detailed reporting of results.
- PhysChem characterization and form selection – We have a wide variety of predictive and analytical tools to confirm and characterize the solid forms and to test their performance. We make expert recommendations on the most favorable form to take forward.
- Crystallization process development – We design practical, robust and scalable crystallization methods that are integrated in the overall manufacturing plan of your API for toxicity testing and clinical trials.
- Preformulation studies – Assessment excipient compatibility, dissolution testing and property assessment to prepare for formulation R&D.
- Late-stage ADME/PK integration – Evaluate how selected polymorphs, salts or co-crystals influence absorption and exposure in preclinical models to ensure the desired form supports both manufacturability and bioavailability.
Solid-state chemistry expertise
20+
years of experience
Extensive work on salt- and polymorph screening, crystallization, and scale-up.
World class laboratory
The most advanced high throughput screening systems and lab automation tools to deliver high quality results.
Rapid project turnaround
High-throughput workflows deliver complete, reliable screening data faster, using only very small quantities of your compound.
Fully integrated teams
Solid-state, process chemists and analytical experts connected in the same facility, ensuring seamless handoffs and reduced project risk.
Integrated preclinical drug development
Solid-state chemistry at Symeres links directly with drug discovery to aid candidate selection and with process development for smooth scale-up to GMP manufacturing.
Our teams connect scale-up for reliable non-GMP tox-grade and GMP drug substance production, and formulation and analytical development to fully characterize each molecule for reliable, ready-to-dose material for first-in-human studies.
What do our partners say?
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
Your discovery and development partner
Symeres support small-molecule programs from discovery through IND with openness, agility and scientific depth. Our connected teams in Europe and North America provide medicinal chemistry, computational chemistry, synthetic chemistry, and specialty chemistry services integrated with biology, ADME-Tox, and CMC development.
We share data transparently, adapt quickly to new results, and stay accountable from first experiments to preclinical and clinical development stages, to keep your progress clear, connected and continuous. Projects can run as standalone studies or as coordinated, multi-disciplinary programs.
Resources we think you'll love
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Whitepaper
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Whitepaper
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our preclinical solid-state chemistry experts
See how we can support the discovery and development of your next breakthrough.